- Price
- $38.78
- Day
- +8.93%
- Mkt Cap
- $2.25B
- 52W Range
- $25.52 – $40.87
- Volume
- 1.97M
- Beta
- 0.91
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
With the Fed holding rates steady and Middle East tensions clouding market sentiment, ARW, PENN, GOOS and HRMY emerge as attractive value opportunities.
Read full article
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read full article
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two stocks presents investors with the better value opportunity right now?
Read full article
Harmony Biosciences (HRMY) is evolving from a single-product firm into a self-funded neuroscience platform, leveraging robust WAKIX growth. WAKIX posted 30% Q1 revenue growth, supporting a strong balance sheet with $710 million net cash and funding for pipeline expansion. HRMY trades at a deep valuation discount, reflecting market fears of WAKIX cash flow erosion post-2030 and underappreciated pipeline potential.
Read full article
Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Harmony Biosciences, Invesco, GM, HPE and Quanex made the screen of low price-to-book stocks that also met multiple value metrics.
Read full article
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Read full article
Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read full article
PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results.
Read full article
Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year, while reaffirming full-year guidance despite a CFO transition.
Read full article
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1. These results underscore continued strong demand for WAKIX, disciplined commercial execution across the franchise and sustained momentum through the fi.
Read full article
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read full article